Document is current
Any future updates will be listed below
-
Authors
Loges, Sonja https://orcid.org/0000-0002-7650-8527
Heuser, Michael https://orcid.org/0000-0001-5318-9044
Chromik, Jörg
Sutamtewagul, Grerk https://orcid.org/0000-0002-1311-6227
Kapp-Schwoerer, Silke
Crugnola, Monica
Di Renzo, Nicola
Lemoli, Roberto
Mattei, Daniele
Fiedler, Walter
Alvarado-Valero, Yesid
Ben-Batalla, Isabel
Waizenegger, Jonas
Rieckmann, Lisa-Marie
Janning, Melanie
Collienne, Maike https://orcid.org/0000-0003-0932-2471
Imbusch, Charles D. https://orcid.org/0000-0003-4920-551X
Beumer, Niklas https://orcid.org/0000-0001-6538-0217
Micklem, David https://orcid.org/0000-0003-2756-2591
H Nilsson, Linn
Madeleine, Noëlly
McCracken, Nigel
Oliva, Cristina
Gorcea-Carson, Claudia
Gjertsen, Bjørn T.
-
Funding
Funding for this research was provided by:
Hector Fellow Academy
BerGenBio (No grant reference number available) Hector Stiftung II
- License Information
-
More Information
Article History
Received: 12 April 2024
Accepted: 14 March 2025
First Online: 23 March 2025
Competing interests
: S.L. received travel support, advisory board honoraria and research funding from BerGenBio. She is currently supported by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (Grant Agreement No. 758713) and by the Hector Stiftung II. M.H. is a consultant, advisor and/or speaker at AbbVie, Amgen, Bristol Myers Squibb, Certara, Glycostem, Jazz, Janssen, LabDelbert, Novartis, Pfizer, PinotBio, Servier and Sobi. His institution received research support from AbbVie, Agios, Astellas, BerGenBio, Bristol Myers Squibb, Glycostem, Jazz, Karyopharm, Loxo Oncology and PinotBio. D. Micklem, L.H.N., N. Madeleine, N. McCracken, C.O., C.G.-C. are employees at BerGenBio and may hold BerGenBio stock or stock options. The other authors declare no competing financial interests.
